Abstract:
Novel phosphonic diester derivatives represented by general formula (1) or pharmacologically acceptable salts thereof which are useful as drugs, wherein R represents amino, N-(lower alkyl)amino, N-(lower alkenyl)amino, etc.; R and R represent each hydrogen, lower alkyl, halogeno, lower alkoxy etc.; R represents hydrogen, lower alkyl or phenyl(lower alkyl); R and R represent each lower alkyl; X, Y and Z are all carbon atoms, or one of X, Y and Z is a nitrogen atom while other two are carbon atoms; and Q represents a single bond or alkylene.
Abstract translation:用作药物的通式(1)表示的新型膦酸二酯衍生物或其药理学上可接受的盐,其中R 1表示氨基,N-(低级烷基)氨基,N-(低级链烯基)氨基等; R 2和R 3各自代表氢,低级烷基,卤代,低级烷氧基等; R 4代表氢,低级烷基或苯基(低级烷基); R 5和R 6代表每个低级烷基; X,Y和Z都是碳原子,或者X,Y和Z中的一个是氮原子,而另外两个是碳原子; Q表示单键或亚烷基。
Abstract:
The invention relates to new piperazinyl-substituted pyridylalkane alkene and alkine acid amides with a saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group according to general formula (I) as well as methods for the production of these compounds, medicaments containing these and their production as well as their therapeutic use, especially as cytostatic agents and immunosuppressive agents, for example in the treatment or prevention of various types of tumors and control of immune reactions such as autoimmune diseases.
Abstract:
The invention concerns a compound of formula (I) in which: R1, R2, R'1, R'2, identical or different, represent a hydrogen, halogen atom, an alkyl, alkoxy, hydroxy, nitro or trihalogenomethyl group, or R1 and R2 (respectively R'1 and R'2) form together with the benzene nucleus which bears them a naphthyl or anthracenyl group; X represents C=T, SO2, CH2, or X-A1-X represents the group (a) in which T represents an oxygen atom or a sulphur atom; A1 represents any one of the groups as defined in the description; A2, A3, identical or different, represent an alkylene group or a single bond; R3, R4, identical or different, represent any one of the groups as defined in the description. The invention also concerns its isomers as well as its additive salts to a pharmaceutically acceptable base. The invention is useful for the preparation of medicines.
Abstract:
To provide an electrochromic compound, represented by the following general formula (I): General Formula (I) where X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are each independently a hydrogen atom or a monovalent substituent; R 1 and R 2 are each independently a monovalent substituent; A- and B- are each independently a monovalent anion; and Y is represented by the following general formula (II) or (III): General Formula (II) General Formula (III) where X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , and X 18 are each independently a hydrogen atom or a monovalent substituent.
Abstract:
The present invention relates to novel phenyl oxazolidinone compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing conditions caused by microbial infections. The compounds of the present invention are effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bacterioides spp., Clostridia spp., H. influenza , Moraxella Spp., as well as acid-fast organisms such as Mycobacterium tuberculosis and the like.
Abstract:
The present invention relates to novel alpha -substituted- beta -aminoethylphosphonate and alpha -substituted- beta -aminovinylphosphonate derivatives and their uses for lowering plasma levels of apo (a), Lp(a), apo B, apo B associated lipoproteins (low density lipoproteins and very low density lipoproteins) and for lowering plasma levels of total cholesterol.